You are here

Article Text

Article menu
Download PDFPDF
Letter
Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease
  1. M Miura1,
  2. H Ohki1,
  3. S Yoshiba1,
  4. H Ueda1,
  5. A Sugaya1,
  6. M Satoh1,
  7. H Yamagishi2
  1. 1Department of Cardiology, Tokyo Metropolitan Kiyose Children’s Hospital, Tokyo, Japan
  2. 2Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan
  1. Correspondence to:
    Dr M Miura

https://doi.org/10.1136/adc.2004.062299

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The efficacy and safety, including arrhythmia and sudden death,1,2 of intravenous methylprednisolone pulse (IVMP) therapy in patients with Kawasaki disease (KD) are uncertain.

    We conducted a control study in KD patients with persistent or recurrent fever (⩾37.5°C) 48 hours after a single infusion of initial intravenous immunoglobulin (IVIG) 2 g/kg. At enrolment (day 1), the subjects were randomised to receive IVMP (30 mg/kg/day of methylprednisolone for three days), or additional IVIG (2 g/kg). Heparin was also continuously infused (15–20 units/kg/h) in the IVMP group. The study was halted prematurely because of …

    View Full Text